MANTIXA

Molsidomine is an

Oral active, long-acting vasodilator, which belongs to the class of medications known as syndnones.

Interestingly, it is being studied as being a preventive measure in cerebral infarction 1.

The indications for use of molsidomine include ischemic heart disease, angina, chronic heart failure, and pulmonary hypertension 9, 10.

Molsidomine leads to smooth muscle relaxation in the coronary blood vessels, relieving symptoms of angina and increasing blood flow to the coronary arteries.

Peak plasma drug concentration (tmax) occurs from 1-2 hours after administration.

Molsidomine hepatically metabolized to linsidomine.

Linsidomine releases nitric oxide (NO) from endothelial cells when it decays, and acts as the active vasodilating metabolite responsible for molsidomine's pharmacological effects.

Oral absorption of

Molsidomine is found to be 95.5% ±4.5.

Presystemic metabolism is noted to be 56% and metabolism is reported extensive by Liver.

Excretion accounts for 95 % and plasma half-life is 5 hr.

renal excretion is the main route of elimination of the metabolites in humans (90% to 95%) About 2% of the ingested drug is excreted unchanged in the urine.

Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.